文献速递心境障碍焦虑、强迫与应激相关障碍

边缘型人格障碍:诊断、临床表现、病因、治疗及争议综述

Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies.
PubMed 文献 · World Psychiatry · 2024-01-01

边缘型人格障碍(BPD)自DSM-III引入后定义标准无重大变化,以自我形象、人际关系和情感不稳定为核心特征,常伴冲动、愤怒、空虚感、 abandonment恐惧、自伤自杀行为及应激相关偏执或分离症状。半结构化访谈可可靠诊断,终生患病率普通人群0.7-2.7%,门诊约12%、住院约22%。心理治疗为一线选择,多种疗法随机对照试验支持,效应量0.50-0.65,但近半数患者反应不足;药物对核心特征无一致疗效,仅对特定共病症状可能有用。

要点

  • BPD以自我形象、人际关系和情感不稳定为核心,伴冲动、愤怒、空虚感、 abandonment恐惧及自伤自杀行为。
  • 半结构化访谈可可靠诊断BPD,终生患病率普通人群0.7-2.7%,门诊约12%、住院约22%。
  • 心理治疗为一线选择,效应量0.50-0.65,但近半数患者反应不足;药物对核心特征无一致疗效。

核心结论

  • BPD可可靠诊断,心理治疗为一线选择,但近半数患者反应不足,药物对核心特征无一致疗效。

研究设计与样本

  • 综述综合BPD诊断、临床特征、危险因素、神经生物学、认知及管理,并讨论争议与研究方向。

主要发现

  • BPD与功能损害、治疗利用高及社会成本高相关,自伤和自杀风险高。
  • BPD与抑郁、物质使用、创伤后应激、注意缺陷多动、双相、神经性贪食及其他人格障碍显著相关。
  • 遗传因素与不良童年经历交互在病因中起核心作用,神经生物学基础尚待阐明。
  • 辩证行为治疗、心智化治疗、移情焦点治疗和图式治疗等获随机对照试验支持,无优劣之分。
  • 心理治疗较常规治疗更有效,核心症状严重度效应量0.50-0.65;药物对核心特征无一致疗效。

关键数值与推荐

  • 普通成人终生患病率0.7-2.7%,门诊精神科约12%,住院精神科约22%。
  • 心理治疗对比常规治疗,核心BPD症状严重度效应量0.50-0.65。
  • 近半数患者对心理治疗反应不足。
  • 药物对BPD核心特征无一致疗效证据,仅对离散严重共病焦虑、抑郁或类精神病性特征可能有用。

临床怎么用

  • 采用半结构化访谈可靠诊断BPD并与其他精神障碍鉴别。
  • 心理治疗为一线选择,可选辩证行为治疗、心智化治疗、移情焦点治疗或图式治疗。
  • 药物不用于核心特征,仅对离散严重共病焦虑、抑郁或类精神病性特征考虑使用。
  • 早期诊断和治疗BPD可减少个体痛苦和社会成本。

局限性

  • 神经生物学基础尚待阐明。
  • 近半数患者对心理治疗反应不足,需进一步研究。
  • 尚不清楚哪些患者可能从特定心理治疗方法中获益更多。
  • 需要更多高质量研究,包括青少年和成人群体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Borderline personality disorder (BPD) was introduced in the DSM-III in 1980. From the DSM-III to the DSM-5, no major changes have occurred in its defining criteria. The disorder is characterized by instability of self-image, interpersonal relationships and affects. Further symptoms include impulsivity, intense anger, feelings of emptiness, strong abandonment fears, suicidal or self-mutilation behavior, and transient stress-related paranoid ideation or severe dissociative symptoms. There is evidence that BPD can be reliably diagnosed and differentiated from other mental disorders by semi-structured interviews. The disorder is associated with considerable functional impairment, intensive treatment utilization, and high societal costs. The risk of self-mutilation and suicide is high. In the general adult population, the lifetime prevalence of BPD has been reported to be from 0.7 to 2.7%, while its prevalence is about 12% in outpatient and 22% in inpatient psychiatric services. BPD is significantly associated with other mental disorders, including depressive disorders, substance use disorders, post-traumatic stress disorder, attention-deficit/hyperactivity disorder, bipolar disorder, bulimia nervosa, and other personality disorders. There is convincing evidence to suggest that the interaction between genetic factors and adverse childhood experiences plays a central role in the etiology of BPD. In spite of considerable research, the neurobiological underpinnings of the disorder remain to be clarified. Psychotherapy is the treatment of choice for BPD. Various approaches have been empirically supported in randomized controlled trials, including dialectical behavior therapy, mentalization-based therapy, transference-focused therapy, and schema therapy. No approach has proved to be superior to others. Compared to treatment as usual, psychotherapy has proved to be more efficacious, with effect sizes between 0.50 and 0.65 with regard to core BPD symptom severity. However, almost half of the patients do not respond sufficiently to psychotherapy, and further research in this area is warranted. It is not clear whether some patients may benefit more from one psychotherapeutic approach than from others. No evidence is available consistently showing that any psychoactive medication is efficacious for the core features of BPD. For discrete and severe comorbid anxiety or depressive symptoms or psychotic-like features, pharmacotherapy may be useful. Early diagnosis and treatment of BPD can reduce individual suffering and societal costs. However, more high-quality studies are required, in both adolescents and adults. This review provides a comprehensive update of the BPD diagnosis and clinical characterization, risk factors, neurobiology, cognition, and management. It also discusses the current controversies concerning the disorder, and highlights the areas in which further research is needed.

来源:World Psychiatry,查看原文。版权归原作者所有。

引用

  1. Leichsenring F, Fonagy P, Heim N, et al. Borderline personality disorder: a comprehensive review of diagnosis and clinical presentation, etiology, treatment, and current controversies. World Psychiatry. 2024. PMID: 38214629. doi:10.1002/wps.21156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。